Inactive Instrument

Global Blood Therapeutics, Inc.

GBT

US37890U1088

Biotechnology & Medical Research

Global Blood Therapeutics, Inc. Announces the Resignation of Deval L. Patrick, Member of the Board of Directors

November 22, 2019 at 02:38 pm EST

On November 22, 2019, Deval L. Patrick, a member of the board of directors of Global Blood Therapeutics, Inc., notified the company of his resignation from the Board, effective immediately.

Latest news about Global Blood Therapeutics, Inc.

BioPharma Credit Receives $175 Million From Global Blood Therapeutics Investment	22-10-06	MT
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from S&P Global BMI Index	22-10-06	CI
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from S&P TMI Index	22-10-06	CI
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from S&P Biotechnology Select Industry Index	22-10-06	CI
Global Blood Therapeutics, Inc. Announces Cessation of Ted W. Love as Chief Executive Officer	22-10-05	CI
Global Blood Therapeutics, Inc. Announces Executive Changes	22-10-05	CI
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Composite Index	22-10-05	CI
Pfizer Inc. completed the acquisition of Global Blood Therapeutics, Inc. from a group of shareholders.	22-10-04	CI
Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Biotechnology Index	22-10-04	CI
Insider Sell: Global Blood Therapeutics	22-09-07	MT
Insider Sell: Global Blood Therapeutics	22-08-19	MT
Biotech stocks pin bounce back hopes on M&A boost	22-08-12	RE
North American Morning Briefing : Caution -2-	22-08-10	DJ
Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Raised to $68.50 From $60 Amid Pfizer Deal	22-08-09	MT
SVB Securities Downgrades Global Blood Therapeutics to Market Perform from Outperform, Sets $68.50 Price Target	22-08-09	MT
Wells Fargo Downgrades Global Blood Therapeutics to Equalweight From Overweight, Adjusts Price Target to $68.50 From $66	22-08-09	MT
Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral From Overweight, Adjusts Price Target to $68.50 From $75	22-08-09	MT
William Blair Downgrades Global Blood Therapeutics to Market Perform From Outperform	22-08-09	MT
Cowen Downgrades Global Blood Therapeutics to Market Perform From Outperform, Adjusts Price Target to $68.50 From $67	22-08-09	MT
North American Morning Briefing : Stocks to -2-	22-08-09	DJ
BioPharma Credit To Receive Loan Prepayment Following Pfizer's Takeover Of Global Blood Therapeutics	22-08-09	MT
Guggenheim Downgrades Global Blood Therapeutics to Neutral From Buy, Sets $68.50 Price Target	22-08-08	MT
Health Care Up Amid Deal Activity -- Health Care Roundup	22-08-08	DJ
Oppenheimer Downgrades Global Blood Therapeutics to Market Perform From Outperform	22-08-08	MT
Wedbush Downgrades Global Blood Therapeutics to Neutral From Outperform on Pfizer Acquisition, Lowers PT to $68.50 From $74	22-08-08	MT

Chart Global Blood Therapeutics, Inc.

Duration

Period

More charts

Global Blood Therapeutics, Inc. is a biopharmaceutical company that discovers, develops and delivers treatments. The Company is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). It is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company's next-generation HbS polymerization inhibitor. The Company is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.68%	49.46B
IQVIA HOLDINGS INC.	+1.56%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.69%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-21.04%	18.64B
BIO-TECHNE CORPORATION	+7.39%	13.16B
MEDPACE HOLDINGS, INC.	+28.64%	12.55B
UNITED THERAPEUTICS CORPORATION	+23.85%	12.1B

Other Biotechnology & Medical Research